Free Access
Méd. Intensive Réa.
Volume 25, Septembre 2016
Médecine d’urgence-Neuroréanimation
Page(s) S179 - S191
Section Mise Au Point / Update
Published online 27 June 2016
  • Molinoff PB, Axelrod J (1971) Biochemistry of catecholamines. Annu Rev Biochem 40:465–500 [CrossRef] [PubMed] [Google Scholar]
  • Eisenhofer G, Kopin IJ, Goldstein DS (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56:331–49 [CrossRef] [PubMed] [Google Scholar]
  • Schulz C, Eisenhofer G, Lehnert H (2004) Principles of catecholamine biosynthesis, metabolism and release. Front Horm Res 31:1–25 [CrossRef] [PubMed] [Google Scholar]
  • Chernow B, Rainey TG, Lake CR (1982) Endogenous and exogenous catecholamines in critical care medicine. Crit Care Med 10:409–16 [CrossRef] [PubMed] [Google Scholar]
  • Steinberg C, Notterman DA (1994) Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors. Clin Pharmacokinet 27:345–67 [PubMed] [Google Scholar]
  • Candito M, Albertini M, Politano S, et al (1993) Plasma catecholamine levels in children. J Chromatogr 617:304–7 [CrossRef] [PubMed] [Google Scholar]
  • Eliot RJ, Lam R, Leake RD, et al (1980) Plasma catecholamine concentrations in infants at birth and during the first 48 hours of life. J Pediatr 96:311–5 [PubMed] [Google Scholar]
  • Humphrey PP, Barnard EA (1998) International Union of Pharmacology. XIX. The IUPHAR receptor code: a proposal for an alphanumeric classification system. Pharmacol Rev 50:271–7 [PubMed] [Google Scholar]
  • Guimaraes S, Moura D (2001) Vascular adrenoceptors: an update. Pharmacol Rev 53:319–56 [PubMed] [Google Scholar]
  • Kozlik R, Kramer HH, Wicht H, et al (1991) Myocardial beta-adrenoceptor density and the distribution of beta 1- and beta 2-adrenoceptor subpopulations in children with congenital heart disease. Eur J Pediatr 150:388–94 [CrossRef] [PubMed] [Google Scholar]
  • Boillot A, Massol J, Maupoil V, et al (1997) Myocardial and vascular adrenergic alterations in a rat model of endotoxin shock: reversal by an anti-tumor necrosis factor-alpha monoclonal antibody. Crit Care Med 25:504–11 [CrossRef] [PubMed] [Google Scholar]
  • Kozlik-Feldmann R, Kramer HH, Wicht H, et al (1993) Distribution of myocardial beta-adrenoceptor subtypes and coupling to the adenylate cyclase in children with congenital heart disease and implications for treatment. J Clin Pharmacol 33:588–95 [PubMed] [Google Scholar]
  • Bernstein D, Doshi R, Huang S, et al (1992) Transcriptional regulation of left ventricular beta-adrenergic receptors during chronic hypoxia. Circ Res 71:1465–71 [PubMed] [Google Scholar]
  • Sato N, Vatner SF, Shen YT, et al (1997) Effects of cardiac denervation on development of heart failure and catecholamine desensitization. Circulation 95:2130–40 [CrossRef] [PubMed] [Google Scholar]
  • Garcia-Sainz JA, Vazquez-Prado J, del Carmen Medina L (2000) Alpha 1-adrenoceptors: function and phosphorylation. Eur J Pharmacol 389:1–12 [CrossRef] [PubMed] [Google Scholar]
  • Booker PD (2002) Pharmacological support for children with myocardial dysfunction. Paediatr Anaesth 12:5–25 [CrossRef] [PubMed] [Google Scholar]
  • Goldberg LI, Kohli JD, Glock D (1986) Conclusive evidence for two subtypes of dopamine receptors. In: Woodruff GN, Poat JA, Roberts PJ (eds) Dopaminergic systems and their regulation, pp 195–212 [CrossRef] [Google Scholar]
  • Henkel JG, Sikand N, Makriyannis A, Gianutsos G (1981) Synthesis and adrenoceptor affinity of some highly polar beta-substituted catecholamines. J Med Chem 24:1258–60 [CrossRef] [PubMed] [Google Scholar]
  • Bangash MN, Kong ML, Pearse RM (2012) Use of inotropes and vasopressor agents in critically ill patients. Br J Pharmacol 165:2015–33 [CrossRef] [PubMed] [Google Scholar]
  • Leone M, Martin C (2008) Vasopressor use in septic shock: an update. Curr Opin Anaesthesiol 21:141–7 [CrossRef] [PubMed] [Google Scholar]
  • Hollenberg SM (2011) Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med 183:847–55 [CrossRef] [PubMed] [Google Scholar]
  • Stratton JR, Pfeifer MA, Ritchie JL, Halter JB (1985) Hemodynamic effects of epinephrine: concentration-effect study in humans. J Appl Physiol 58:1199–206 [CrossRef] [PubMed] [Google Scholar]
  • Ensinger H, Weichel T, Lindner KH, et al (1993) Effects of norepinephrine, epinephrine, and dopamine infusions on oxygen consumption in volunteers. Crit Care Med 21:1502–8 [CrossRef] [PubMed] [Google Scholar]
  • Duranteau J, Sitbon P, Teboul JL, et al (1999) Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. Crit Care Med 27:893–900 [CrossRef] [PubMed] [Google Scholar]
  • Hoffman BB, Lefkowitz RJ (1996) Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Goodman and Gillman's (eds) The pharmacologial basis of therapeutics the McGraw-Hill Companies, Inc, pp 232–42 [Google Scholar]
  • Moran JL, O'Fathartaigh MS, Peisach AR, et al (1993) Epinephrine as an inotropic agent in septic shock: a dose-profile analysis. Crit Care Med 21:70–7 [CrossRef] [PubMed] [Google Scholar]
  • Clutter WE, Bier DM, Shah SD, Cryer PE (1980) Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest 66:94–101 [CrossRef] [PubMed] [Google Scholar]
  • Aviado DM Jr., Schmidt CF (1957) Effects of sympathomimetic drugs on pulmonary circulation: with special reference to a new pulmonary vasodilator. J Pharmacol Exp Ther 120:512–27 [PubMed] [Google Scholar]
  • Bearn AG, Billing B, Sherlock S (1951) The effect of adrenaline and noradrenaline on hepatic blood flow and splanchnic carbohydrate metabolism in man. J Physiol 115:430–41 [CrossRef] [PubMed] [Google Scholar]
  • Barcroft H, Konzett H (1949) Action of noradrenaline and adrenaline on human heart-rate. Lancet 1:147 [Google Scholar]
  • Martin C, Perrin G, Saux P, et al (1994) Effects of norepinephrine on right ventricular function in septic shock patients. Intensive Care Med 20:444–7 [CrossRef] [PubMed] [Google Scholar]
  • Barcroft H, Konzett H (1949) A comparison of the actions of noradrenaline and adrenaline on the blood vessels of human skeletal muscle. J Physiol 110:1–2 [CrossRef] [PubMed] [Google Scholar]
  • Frishman WH, Hotchkiss H (1996) Selective and nonselective dopamine receptor agonists: an innovative approach to cardiovascular disease treatment. Am Heart J 132:861–70 [PubMed] [Google Scholar]
  • Hoogenberg K, Smit AJ, Girbes AR (1998) Effects of low-dose dopamine on renal and systemic hemodynamics during incremental norepinephrine infusion in healthy volunteers. Crit Care Med 26:260–5 [CrossRef] [PubMed] [Google Scholar]
  • Martin C, Papazian L, Perrin G, et al (1993) Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 103:1826–31 [CrossRef] [PubMed] [Google Scholar]
  • Ruffolo RR Jr, Yaden EL (1983) Vascular effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther 224:46–50 [PubMed] [Google Scholar]
  • Gutierrez G, Clark C, Brown SD, et al (1994) Effect of dobutamine on oxygen consumption and gastric mucosal pH in septic patients. Am J Respir Crit Care Med 150:324–9 [CrossRef] [PubMed] [Google Scholar]
  • Nielsen H, Hasenkam JM, Pilegaard HK, et al (1992) Age-dependent changes in alpha-adrenoceptor-mediated contractility of isolated human resistance arteries. Am J Physiol 263:H1190–H6 [CrossRef] [PubMed] [Google Scholar]
  • Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445–79 [CrossRef] [PubMed] [Google Scholar]
  • Urien S (2002) Approches de population et modélisation en pharmacologie. La lettre du Pharmacologue 16:79–81 [Google Scholar]
  • Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303–32 [PubMed] [Google Scholar]
  • Boucher BA, Wood GC, Swanson JM (2006) Pharmacokinetic changes in critical illness. Crit Care Clin 22:255–71, vi [PubMed] [Google Scholar]
  • MacGregor DA, Smith TE, Prielipp RC, et al (2000) Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 92:338–46 [CrossRef] [PubMed] [Google Scholar]
  • Johnston AJ, Steiner LA, O'Connell M, et al (2004) Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients. Intensive Care Med 30:45–50 [CrossRef] [PubMed] [Google Scholar]
  • Notterman DA, Greenwald BM, Moran F, et al (1990) Dopamine clearance in critically ill infants and children: effect of age and organ system dysfunction. Clin Pharmacol Ther 48:138–47 [CrossRef] [PubMed] [Google Scholar]
  • Romero TE, Friedman WF (1979) Limited left ventricular response to volume overload in the neonatal period: a comparative study with the adult animal. Pediatr Res 13:910–5 [CrossRef] [PubMed] [Google Scholar]
  • Padbury JF, Agata Y, Baylen BG, et al (1987) Dopamine pharmacokinetics in critically ill newborn infants. J Pediatr 110:293–8 [PubMed] [Google Scholar]
  • Klem C, Dasta JF, Reilley TE, Flancbaum LJ (1994) Variability in dobutamine pharmacokinetics in unstable critically ill surgical patients. Crit Care Med 22:1926–32 [CrossRef] [PubMed] [Google Scholar]
  • Ahonen J, Aranko K, Iivanainen A, et al (2008) Pharmacokinetic–pharmacodynamic relationship of dobutamine and heart rate, stroke volume and cardiac output in healthy volunteers. Clin Drug Investig 28:121–7 [Google Scholar]
  • Mahoney L, Shah G, Crook D, et al (2016) A literature review of the pharmacokinetics and pharmacodynamics of dobutamine in neonates. Pediatr Cardiol 37:14–23 [CrossRef] [PubMed] [Google Scholar]
  • Ensinger H, Lindner KH, Dirks B, et al (1992) Adrenaline: relationship between infusion rate, plasma concentration, metabolic and haemodynamic effects in volunteers. Eur J Anaesthesiol 9:435–46 [PubMed] [Google Scholar]
  • Abboud I, Lerolle N, Urien S, et al (2009) Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status. Crit Care 13:R120 [CrossRef] [PubMed] [Google Scholar]
  • Ventura AM, Shieh HH, Bousso A, et al (2015) Double-blind prospective randomized controlled trial of dopamine versus epinephrine as first-line vasoactive drugs in pediatric septic shock. Crit Care Med 43:2292–302 [CrossRef] [PubMed] [Google Scholar]
  • Valverde E, Pellicer A, Madero R, et al (2006) Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes. Pediatrics 117:e1213–e22 [PubMed] [Google Scholar]
  • Fisher DG, Schwartz PH, Davis AL (1993) Pharmacokinetics of exogenous epinephrine in critically ill children. Crit Care Med 21:111–7 [CrossRef] [PubMed] [Google Scholar]
  • Oualha M, Urien S, Spreux-Varoquaux O, et al (2014) Pharmacokinetics, hemodynamic and metabolic effects of epinephrine to prevent post-operative low cardiac output syndrome in children. Crit Care 18:R23 [CrossRef] [PubMed] [Google Scholar]
  • Beloeil H, Mazoit JX, Benhamou D, Duranteau J (2005) Norepinephrine kinetics and dynamics in septic shock and trauma patients. Br J Anaesth 95:782–8 [CrossRef] [PubMed] [Google Scholar]
  • Ensinger H, Stein B, Jager O, et al (1992) Relationship between infusion rates, plasma concentrations, and cardiovascular and metabolic effects during the infusion of norepinephrine in healthy volunteers. Crit Care Med 20:1250–6 [CrossRef] [PubMed] [Google Scholar]
  • Lampin ME, Rousseaux J, Botte A, et al (2012) Noradrenaline use for septic shock in children: doses, routes of administration and complications. Acta Paediatr 101:e426–e30 [CrossRef] [PubMed] [Google Scholar]
  • Oualha M, Treluyer JM, Lesage F, et al (2014) Population pharmacokinetics and haemodynamic effects of norepinephrine in hypotensive critically ill children. Br J Clin Pharmacol 78:886–97 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.